This company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsTitan Pharmaceuticals (TTNP) 주식 개요는 큰 규모의 사업을 운영하고 있지 않습니다. 자세히 보기TTNP 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성5/6배당0/6강점지난 5년 동안 수입이 매년 3.7% 증가했습니다.위험 분석수익이 USD$1m 미만입니다($0)의미 있는 시가총액이 없습니다($6M)cash runway 경력이 1년 미만입니다.지난 1년 동안 주주가 크게 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기TTNP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$4.61해당 없음내재 할인율Est. Revenue$PastFuture-16m15m2016201920222025202620282031Revenue US$0.003Earnings US$0.0004AdvancedSet Fair ValueView all narrativesTitan Pharmaceuticals, Inc. 경쟁사ProPhase LabsSymbol: OTCPK:PRPHMarket cap: US$856.4kcbdMDSymbol: NYSEAM:YCBDMarket cap: US$8.2mChina Pharma HoldingsSymbol: NYSEAM:CPHIMarket cap: US$30.9mCNS PharmaceuticalsSymbol: NasdaqCM:CNSPMarket cap: US$7.4m가격 이력 및 성과Titan Pharmaceuticals 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$4.6152주 최고가US$5.7652주 최저가US$3.03베타1.411개월 변동16.41%3개월 변동4.77%1년 변동-12.02%3년 변동-79.05%5년 변동-95.12%IPO 이후 변동-100.00%최근 뉴스 및 업데이트공시 • Jun 29Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.COn June 27, 2025, Titan Pharmaceuticals, Inc. closed the transaction.공시 • Apr 24Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025. Location: offices of olshan frome wolosky llp, located at 1325 avenue of the americas, 15th floor, new york 10019, new york, United States공시 • Jan 09Titan Pharmaceuticals Receives Nasdaq Non-Compliance Notice Regarding Listing Rules 5620(a) and 5810(c)(2)(G)On January 3, 2025, Titan Pharmaceuticals, Inc. (the Company") received a notice (the Notice") from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (Nasdaq") that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2023 fiscal year end. The Notice has no immediate effect on the Company's listing on the Nasdaq Capital Market. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company may be granted an exception of up to 180 calendar days from the date of its December 31, 2024 fiscal year end, or until June 30, 2025, to regain compliance. The Company's failure to regain compliance with standards for continued listing would result in the ultimate de-listing of its common stock from Nasdaq. In response to the Notice, the Company intends to schedule an annual meeting of shareholders and to submit a plan designed to regain compliance in accordance with the requirements of the Notice and the Nasdaq listing standards.공시 • Nov 28Titan Pharmaceuticals Announces Receipt of Notice from NasdaqTitan Pharmaceuticals, Inc. reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q3 Form 10-Q”) in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Third Quarter Form 10-Q, or until May 19, 2025, to regain compliance. In response to the Notice, the Company is working to file the Third Quarter Form 10-Q as soon as possible in order to regain compliance with the Listing Rule. However, if the Company does not submit the Third Quarter Form 10-Q by January 21, 2025, the Company will submit a plan by such date to Nasdaq that outlines, as definitively as possible, the steps the Company will take to promptly file the Third Quarter Form 10-Q. Additionally, on November 25, 2024, the Company received a notice (the “5605 Notice”) from Nasdaq advising the Company that, following the appointment of Brynner Chiam as Acting Principal Executive Officer and Acting Principal Financial Officer of the Company on November 6, 2024, the Company no longer complies with Nasdaq’s audit committee requirements as set in Listing Rule 5605 (“Rule 5605”). Nasdaq advised that consistent with Listing Rule 5605(c)(4), Nasdaq will provide the Company with a cure period in order to regain compliance with Rule 5605: (i) until the earlier of the Company’s next annual shareholders’ meeting or November 6, 2025; or (ii) if the next annual shareholders’ meeting is held before May 5, 2025, then the Company must evidence compliance no later than May 5, 2025. The Company intends to appoint an additional independent director to the Board of Directors and the Audit Committee prior to the end of the cure periods.공시 • Nov 16Titan Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2024, Titan Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Oct 25Titan Pharmaceuticals, Inc. Announces Resignation of Dato’ Seow Gim Shen as Chairman of the BoardOn October 24, 2024, Dato’ Seow Gim Shen notified the Board of Directors of Titan Pharmaceuticals, Inc. of his decision to resign as Chairman of the Board of the Company. Mr. Shen indicated that his decision to resign was for personal reasons and not as a result of any disagreement with the Board or the Company’s management on any matter relating to the Company’s operations, policies or practices. The Company has launched a search to identify a suitable replacement for Mr. Shen. The Company anticipates that the resignation of Mr. Shen will not impact the previously announced business combination with KE Sdn. Bhd. currently being pursued by the Company.더 많은 업데이트 보기Recent updates공시 • Jun 29Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.COn June 27, 2025, Titan Pharmaceuticals, Inc. closed the transaction.공시 • Apr 24Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025. Location: offices of olshan frome wolosky llp, located at 1325 avenue of the americas, 15th floor, new york 10019, new york, United States공시 • Jan 09Titan Pharmaceuticals Receives Nasdaq Non-Compliance Notice Regarding Listing Rules 5620(a) and 5810(c)(2)(G)On January 3, 2025, Titan Pharmaceuticals, Inc. (the Company") received a notice (the Notice") from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (Nasdaq") that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2023 fiscal year end. The Notice has no immediate effect on the Company's listing on the Nasdaq Capital Market. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company may be granted an exception of up to 180 calendar days from the date of its December 31, 2024 fiscal year end, or until June 30, 2025, to regain compliance. The Company's failure to regain compliance with standards for continued listing would result in the ultimate de-listing of its common stock from Nasdaq. In response to the Notice, the Company intends to schedule an annual meeting of shareholders and to submit a plan designed to regain compliance in accordance with the requirements of the Notice and the Nasdaq listing standards.공시 • Nov 28Titan Pharmaceuticals Announces Receipt of Notice from NasdaqTitan Pharmaceuticals, Inc. reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q3 Form 10-Q”) in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Third Quarter Form 10-Q, or until May 19, 2025, to regain compliance. In response to the Notice, the Company is working to file the Third Quarter Form 10-Q as soon as possible in order to regain compliance with the Listing Rule. However, if the Company does not submit the Third Quarter Form 10-Q by January 21, 2025, the Company will submit a plan by such date to Nasdaq that outlines, as definitively as possible, the steps the Company will take to promptly file the Third Quarter Form 10-Q. Additionally, on November 25, 2024, the Company received a notice (the “5605 Notice”) from Nasdaq advising the Company that, following the appointment of Brynner Chiam as Acting Principal Executive Officer and Acting Principal Financial Officer of the Company on November 6, 2024, the Company no longer complies with Nasdaq’s audit committee requirements as set in Listing Rule 5605 (“Rule 5605”). Nasdaq advised that consistent with Listing Rule 5605(c)(4), Nasdaq will provide the Company with a cure period in order to regain compliance with Rule 5605: (i) until the earlier of the Company’s next annual shareholders’ meeting or November 6, 2025; or (ii) if the next annual shareholders’ meeting is held before May 5, 2025, then the Company must evidence compliance no later than May 5, 2025. The Company intends to appoint an additional independent director to the Board of Directors and the Audit Committee prior to the end of the cure periods.공시 • Nov 16Titan Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2024, Titan Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Oct 25Titan Pharmaceuticals, Inc. Announces Resignation of Dato’ Seow Gim Shen as Chairman of the BoardOn October 24, 2024, Dato’ Seow Gim Shen notified the Board of Directors of Titan Pharmaceuticals, Inc. of his decision to resign as Chairman of the Board of the Company. Mr. Shen indicated that his decision to resign was for personal reasons and not as a result of any disagreement with the Board or the Company’s management on any matter relating to the Company’s operations, policies or practices. The Company has launched a search to identify a suitable replacement for Mr. Shen. The Company anticipates that the resignation of Mr. Shen will not impact the previously announced business combination with KE Sdn. Bhd. currently being pursued by the Company.공시 • Aug 20Ke Sdn. Bhd. entered into an agreement to acquire Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $21.6 million in a reverse merger transaction.Ke Sdn. Bhd. entered into an agreement to acquire Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $21.6 million in a reverse merger transaction on August 19, 2024. Upon completion of the merger, the existing security holders of Ke Sdn. Bhd. ("KE") and Titan (excluding The Sire Group Ltd. and current Titan directors and officers) expect to own approximately 86.7% and 13.3%, respectively, of the outstanding shares of the combined company. It is expected that Dato’ Seow Gim Shen will own 48.9% of the outstanding shares of the combined company following the merger. Completion of the merger is subject to the approval of the merger by Titan’s stockholders, the registration statement shall have become effective, shares to be issued in connection with the transaction shall have been approved for listing on Nasdaq and satisfaction or waiver of other customary conditions. The agreement was unanimously approved by Titan’s board of directors. KE board of directors also approved the transaction. Kenneth Schlesinger and Claudia Dubon of Olshan Frome Wolosky LLP acted as legal advisor to Titan. Mitchell S. Nussbaum of Loeb & Loeb LLP acted as legal advisor to KE.공시 • Aug 16Titan Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/15/2024, Titan Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 27Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million. Security Name: Common Stock Security Type: Common Stock공시 • Jan 19Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024Titan Pharmaceuticals, Inc. announced that on January 11, 2024, Brian Crowley gave notice of his resignation as Senior Vice President, Finance and Administration of the company, effective February 2, 2024. Mr. Crowley served as the Company’s principal accounting officer. The board of directors has initiated a search process for a new principal accounting officer. Mr. Crowley will continue to assist the Company through February 2, 2024 in order to ensure a successful transition.Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)Third quarter 2023 results: US$0.023 loss per share (improved from US$0.18 loss in 3Q 2022). Net loss: US$338.0k (loss narrowed 87% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.Board Change • Nov 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. President, COO & Director Kate Beebe-DeVarney is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Sep 21Titan Pharmaceuticals, Inc. Announces Board ResignationsTitan Pharmaceuticals, Inc. announced that the pursuant to the Purchase Agreement, David Lazar and Peter Chasey submitted their resignations from the Company’s Board of Directors, which resignations are effective immediately upon the appointment of two replacement directors to fill the vacancies. The resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. Mr. Lazar will remain with the Company as Chief Executive Officer.공시 • Sep 19+ 1 more updateTitan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group LtdTitan Pharmaceuticals, Inc. announced that it has entered into a definitive securities purchase agreement with new investor, Sire Group Ltd to issue 950,000 designated Series AA Convertible Preferred Stock shares at a price of $10 per share for the gross proceeds of $9,500,000 consisting of $5 million in cash at closing and $4.5 million in the form of a promissory note from Sire Group Ltd on September 18, 2023. The shares have a conversion price of $0.466. The transaction is expected to close on September 23, 2023.Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022)Second quarter 2023 results: US$0.11 loss per share (improved from US$0.18 loss in 2Q 2022). Revenue: US$83.0k (down 45% from 2Q 2022). Net loss: US$1.59m (loss narrowed 36% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.공시 • Jul 29Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million on July 27, 2023. Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing, $1 million to be held in escrow pending completion of certain conditions) with potential milestone payments to Titan of up to $50 million on future net sales of the products. Titan would also receive single digit royalties on future net sales of the products. Additionally, Fedson will assume all liabilities related to a pending employment claim against Titan. The transaction is expected to close 10 days following signing of the Agreement.공시 • Jul 08Titan Pharmaceuticals, Inc. Announces Board ChangesOn July 6, 2023, the Board of Directors of Titan Pharmaceuticals, Inc. held a meeting at which it determined that a majority of the Board is comprised of independent directors in accordance with Nasdaq Listing Rule 5605(b)(1)(A). The Board also determined the composition of the Board committees for the upcoming year. The committees of the Board will be constituted as follows: Audit Committee: David Natan (Chair), Eric Greenberg, Matthew McMurdo, Compensation Committee: Matthew McMurdo (Chair), Peter Chasey, David Natan and Nominating and Governance Committee: Avraham Ben-Tzvi (Chair), Peter Chasey, Eric Greenberg.New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.1m free cash flow). Negative equity (-US$312k). Revenue is less than US$1m (US$463k revenue). Market cap is less than US$10m (US$9.76m market cap). Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding).공시 • Jun 07Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)On June 5, 2023, Titan Pharmaceuticals, Inc. received a letter (the “Extension Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it had been granted an additional 180-day period, or until October 2, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1). As previously disclosed on April 11, 2023, the Company received a notice (the “Notice”) on April 5, 2023 from the Staff notifying the Company that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2022 (“2022 10-K”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2,500,000 (the “Stockholders’ Equity Requirement”). In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy the Stockholders’ Equity Requirement. The Company submitted a plan to regain compliance with the Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1) on May 22, 2023. Pursuant to the Extension Notice, the Company must demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) on or before October 2, 2023, by furnishing to the Securities and Exchange Commission (the “SEC”) and Nasdaq certain information and representations on a Current Report on Form 8-K, among other obligations. If, after submitting this information to the SEC and Nasdaq as described in the Extension Notice, the Company fails to evidence compliance with Nasdaq Listing Rule 5550(b)(1) upon filing its Form 10-K for the year ended December 31, 2023, the Company may be subject to delisting from Nasdaq. In the event the Company fails to regain compliance, Nasdaq will issue the Company a delisting notice, at which time the Company would have the right to a hearing before an independent panel. The hearing request would halt any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.Reported Earnings • May 18First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022)First quarter 2023 results: US$0.11 loss per share (improved from US$0.24 loss in 1Q 2022). Revenue: US$98.0k (down 49% from 1Q 2022). Net loss: US$1.68m (loss narrowed 34% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Jan 28Principal Executive Officer recently bought US$56k worth of stockOn the 25th of January, David Lazar bought around 58k shares on-market at roughly US$0.98 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. David has been a buyer over the last 12 months, purchasing a net total of US$3.9m worth in shares.Board Change • Nov 17Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Jim McNab was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Aug 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Jim McNab was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Aug 12Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021)Second quarter 2022 results: US$0.18 loss per share (down from US$0.17 loss in 2Q 2021). Revenue: US$150.0k (down 66% from 2Q 2021). Net loss: US$2.46m (loss widened 47% from 2Q 2021). Over the next year, revenue is expected to shrink by 87% compared to a 16% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.분석 기사 • Jul 10Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Recent Insider Transactions • Jul 09Insider recently bought US$1.7m worth of stockOn the 7th of July, David Lazar bought around 2m shares on-market at roughly US$0.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$3.8m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jun 10Insider recently bought US$348k worth of stockOn the 8th of June, David Lazar bought around 752k shares on-market at roughly US$0.46 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$506k more in shares than they have sold in the last 12 months.Reported Earnings • May 18First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021)First quarter 2022 results: US$0.24 loss per share (up from US$0.28 loss in 1Q 2021). Revenue: US$192.0k (down 72% from 1Q 2021). Net loss: US$2.54m (loss narrowed 3.8% from 1Q 2021).Recent Insider Transactions • Apr 27Insider recently bought US$157k worth of stockOn the 18th of April, David Lazar bought around 171k shares on-market at roughly US$0.92 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Mar 28Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020)Full year 2021 results: US$0.90 loss per share. Revenue: US$1.53m (down 69% from FY 2020). Net loss: US$8.78m (loss widened 19% from FY 2020).Reported Earnings • Nov 21Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: US$264.0k (down 74% from 3Q 2020). Net loss: US$1.92m (loss widened 32% from 3Q 2020).Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: US$445.0k (down 66% from 2Q 2020). Net loss: US$1.68m (loss narrowed 64% from 2Q 2020).Reported Earnings • May 19First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: US$682.0k (down 49% from 1Q 2020). Net loss: US$2.64m (loss narrowed 53% from 1Q 2020).Is New 90 Day High Low • Mar 05New 90-day low: US$2.88The company is down 18% from its price of US$3.50 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.주주 수익률TTNPUS PharmaceuticalsUS 시장7D7.6%4.9%1.0%1Y-12.0%44.2%28.7%전체 주주 수익률 보기수익률 대 산업: TTNP은 지난 1년 동안 44.2%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: TTNP은 지난 1년 동안 28.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.주가 변동성Is TTNP's price volatile compared to industry and market?TTNP volatilityTTNP Average Weekly Movement12.6%Pharmaceuticals Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%안정적인 주가: TTNP의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: TTNP의 주간 변동성(13%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트19914Weei Chaywww.titanpharm.com타이탄 파마슈티컬스는 이렇다 할 사업을 운영하고 있지 않습니다. 이전에는 만성 질환 치료를 위한 치료제 개발에 종사했습니다. 는 1991년에 설립되었으며 미국 뉴욕에 본사를 두고 있습니다.더 보기Titan Pharmaceuticals, Inc. 기초 지표 요약Titan Pharmaceuticals의 순이익과 매출은 시가총액과 어떻게 비교됩니까?TTNP 기초 통계시가총액US$6.37m순이익 (TTM)-US$2.80m매출 (TTM)n/a0.0x주가매출비율(P/S)-2.2x주가수익비율(P/E)TTNP는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표TTNP 손익계산서 (TTM)매출US$0매출원가US$0총이익US$0기타 비용US$2.81m순이익-US$2.80m최근 보고된 실적Jun 30, 2025다음 실적 발표일해당 없음주당순이익(EPS)-2.11총이익률0.00%순이익률0.00%부채/자본 비율0%TTNP의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/10/01 05:48종가2025/10/01 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Titan Pharmaceuticals, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Benjamin HaynorAlliance Global PartnersJason McCarthyMaxim GroupScott HenryRoth Capital Partners
공시 • Jun 29Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.COn June 27, 2025, Titan Pharmaceuticals, Inc. closed the transaction.
공시 • Apr 24Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025. Location: offices of olshan frome wolosky llp, located at 1325 avenue of the americas, 15th floor, new york 10019, new york, United States
공시 • Jan 09Titan Pharmaceuticals Receives Nasdaq Non-Compliance Notice Regarding Listing Rules 5620(a) and 5810(c)(2)(G)On January 3, 2025, Titan Pharmaceuticals, Inc. (the Company") received a notice (the Notice") from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (Nasdaq") that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2023 fiscal year end. The Notice has no immediate effect on the Company's listing on the Nasdaq Capital Market. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company may be granted an exception of up to 180 calendar days from the date of its December 31, 2024 fiscal year end, or until June 30, 2025, to regain compliance. The Company's failure to regain compliance with standards for continued listing would result in the ultimate de-listing of its common stock from Nasdaq. In response to the Notice, the Company intends to schedule an annual meeting of shareholders and to submit a plan designed to regain compliance in accordance with the requirements of the Notice and the Nasdaq listing standards.
공시 • Nov 28Titan Pharmaceuticals Announces Receipt of Notice from NasdaqTitan Pharmaceuticals, Inc. reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q3 Form 10-Q”) in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Third Quarter Form 10-Q, or until May 19, 2025, to regain compliance. In response to the Notice, the Company is working to file the Third Quarter Form 10-Q as soon as possible in order to regain compliance with the Listing Rule. However, if the Company does not submit the Third Quarter Form 10-Q by January 21, 2025, the Company will submit a plan by such date to Nasdaq that outlines, as definitively as possible, the steps the Company will take to promptly file the Third Quarter Form 10-Q. Additionally, on November 25, 2024, the Company received a notice (the “5605 Notice”) from Nasdaq advising the Company that, following the appointment of Brynner Chiam as Acting Principal Executive Officer and Acting Principal Financial Officer of the Company on November 6, 2024, the Company no longer complies with Nasdaq’s audit committee requirements as set in Listing Rule 5605 (“Rule 5605”). Nasdaq advised that consistent with Listing Rule 5605(c)(4), Nasdaq will provide the Company with a cure period in order to regain compliance with Rule 5605: (i) until the earlier of the Company’s next annual shareholders’ meeting or November 6, 2025; or (ii) if the next annual shareholders’ meeting is held before May 5, 2025, then the Company must evidence compliance no later than May 5, 2025. The Company intends to appoint an additional independent director to the Board of Directors and the Audit Committee prior to the end of the cure periods.
공시 • Nov 16Titan Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2024, Titan Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Oct 25Titan Pharmaceuticals, Inc. Announces Resignation of Dato’ Seow Gim Shen as Chairman of the BoardOn October 24, 2024, Dato’ Seow Gim Shen notified the Board of Directors of Titan Pharmaceuticals, Inc. of his decision to resign as Chairman of the Board of the Company. Mr. Shen indicated that his decision to resign was for personal reasons and not as a result of any disagreement with the Board or the Company’s management on any matter relating to the Company’s operations, policies or practices. The Company has launched a search to identify a suitable replacement for Mr. Shen. The Company anticipates that the resignation of Mr. Shen will not impact the previously announced business combination with KE Sdn. Bhd. currently being pursued by the Company.
공시 • Jun 29Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.COn June 27, 2025, Titan Pharmaceuticals, Inc. closed the transaction.
공시 • Apr 24Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025. Location: offices of olshan frome wolosky llp, located at 1325 avenue of the americas, 15th floor, new york 10019, new york, United States
공시 • Jan 09Titan Pharmaceuticals Receives Nasdaq Non-Compliance Notice Regarding Listing Rules 5620(a) and 5810(c)(2)(G)On January 3, 2025, Titan Pharmaceuticals, Inc. (the Company") received a notice (the Notice") from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (Nasdaq") that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2023 fiscal year end. The Notice has no immediate effect on the Company's listing on the Nasdaq Capital Market. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company may be granted an exception of up to 180 calendar days from the date of its December 31, 2024 fiscal year end, or until June 30, 2025, to regain compliance. The Company's failure to regain compliance with standards for continued listing would result in the ultimate de-listing of its common stock from Nasdaq. In response to the Notice, the Company intends to schedule an annual meeting of shareholders and to submit a plan designed to regain compliance in accordance with the requirements of the Notice and the Nasdaq listing standards.
공시 • Nov 28Titan Pharmaceuticals Announces Receipt of Notice from NasdaqTitan Pharmaceuticals, Inc. reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q3 Form 10-Q”) in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Third Quarter Form 10-Q, or until May 19, 2025, to regain compliance. In response to the Notice, the Company is working to file the Third Quarter Form 10-Q as soon as possible in order to regain compliance with the Listing Rule. However, if the Company does not submit the Third Quarter Form 10-Q by January 21, 2025, the Company will submit a plan by such date to Nasdaq that outlines, as definitively as possible, the steps the Company will take to promptly file the Third Quarter Form 10-Q. Additionally, on November 25, 2024, the Company received a notice (the “5605 Notice”) from Nasdaq advising the Company that, following the appointment of Brynner Chiam as Acting Principal Executive Officer and Acting Principal Financial Officer of the Company on November 6, 2024, the Company no longer complies with Nasdaq’s audit committee requirements as set in Listing Rule 5605 (“Rule 5605”). Nasdaq advised that consistent with Listing Rule 5605(c)(4), Nasdaq will provide the Company with a cure period in order to regain compliance with Rule 5605: (i) until the earlier of the Company’s next annual shareholders’ meeting or November 6, 2025; or (ii) if the next annual shareholders’ meeting is held before May 5, 2025, then the Company must evidence compliance no later than May 5, 2025. The Company intends to appoint an additional independent director to the Board of Directors and the Audit Committee prior to the end of the cure periods.
공시 • Nov 16Titan Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2024, Titan Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Oct 25Titan Pharmaceuticals, Inc. Announces Resignation of Dato’ Seow Gim Shen as Chairman of the BoardOn October 24, 2024, Dato’ Seow Gim Shen notified the Board of Directors of Titan Pharmaceuticals, Inc. of his decision to resign as Chairman of the Board of the Company. Mr. Shen indicated that his decision to resign was for personal reasons and not as a result of any disagreement with the Board or the Company’s management on any matter relating to the Company’s operations, policies or practices. The Company has launched a search to identify a suitable replacement for Mr. Shen. The Company anticipates that the resignation of Mr. Shen will not impact the previously announced business combination with KE Sdn. Bhd. currently being pursued by the Company.
공시 • Aug 20Ke Sdn. Bhd. entered into an agreement to acquire Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $21.6 million in a reverse merger transaction.Ke Sdn. Bhd. entered into an agreement to acquire Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $21.6 million in a reverse merger transaction on August 19, 2024. Upon completion of the merger, the existing security holders of Ke Sdn. Bhd. ("KE") and Titan (excluding The Sire Group Ltd. and current Titan directors and officers) expect to own approximately 86.7% and 13.3%, respectively, of the outstanding shares of the combined company. It is expected that Dato’ Seow Gim Shen will own 48.9% of the outstanding shares of the combined company following the merger. Completion of the merger is subject to the approval of the merger by Titan’s stockholders, the registration statement shall have become effective, shares to be issued in connection with the transaction shall have been approved for listing on Nasdaq and satisfaction or waiver of other customary conditions. The agreement was unanimously approved by Titan’s board of directors. KE board of directors also approved the transaction. Kenneth Schlesinger and Claudia Dubon of Olshan Frome Wolosky LLP acted as legal advisor to Titan. Mitchell S. Nussbaum of Loeb & Loeb LLP acted as legal advisor to KE.
공시 • Aug 16Titan Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/15/2024, Titan Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 27Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million. Security Name: Common Stock Security Type: Common Stock
공시 • Jan 19Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024Titan Pharmaceuticals, Inc. announced that on January 11, 2024, Brian Crowley gave notice of his resignation as Senior Vice President, Finance and Administration of the company, effective February 2, 2024. Mr. Crowley served as the Company’s principal accounting officer. The board of directors has initiated a search process for a new principal accounting officer. Mr. Crowley will continue to assist the Company through February 2, 2024 in order to ensure a successful transition.
Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)Third quarter 2023 results: US$0.023 loss per share (improved from US$0.18 loss in 3Q 2022). Net loss: US$338.0k (loss narrowed 87% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.
Board Change • Nov 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. President, COO & Director Kate Beebe-DeVarney is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Sep 21Titan Pharmaceuticals, Inc. Announces Board ResignationsTitan Pharmaceuticals, Inc. announced that the pursuant to the Purchase Agreement, David Lazar and Peter Chasey submitted their resignations from the Company’s Board of Directors, which resignations are effective immediately upon the appointment of two replacement directors to fill the vacancies. The resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. Mr. Lazar will remain with the Company as Chief Executive Officer.
공시 • Sep 19+ 1 more updateTitan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group LtdTitan Pharmaceuticals, Inc. announced that it has entered into a definitive securities purchase agreement with new investor, Sire Group Ltd to issue 950,000 designated Series AA Convertible Preferred Stock shares at a price of $10 per share for the gross proceeds of $9,500,000 consisting of $5 million in cash at closing and $4.5 million in the form of a promissory note from Sire Group Ltd on September 18, 2023. The shares have a conversion price of $0.466. The transaction is expected to close on September 23, 2023.
Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022)Second quarter 2023 results: US$0.11 loss per share (improved from US$0.18 loss in 2Q 2022). Revenue: US$83.0k (down 45% from 2Q 2022). Net loss: US$1.59m (loss narrowed 36% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.
공시 • Jul 29Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million on July 27, 2023. Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing, $1 million to be held in escrow pending completion of certain conditions) with potential milestone payments to Titan of up to $50 million on future net sales of the products. Titan would also receive single digit royalties on future net sales of the products. Additionally, Fedson will assume all liabilities related to a pending employment claim against Titan. The transaction is expected to close 10 days following signing of the Agreement.
공시 • Jul 08Titan Pharmaceuticals, Inc. Announces Board ChangesOn July 6, 2023, the Board of Directors of Titan Pharmaceuticals, Inc. held a meeting at which it determined that a majority of the Board is comprised of independent directors in accordance with Nasdaq Listing Rule 5605(b)(1)(A). The Board also determined the composition of the Board committees for the upcoming year. The committees of the Board will be constituted as follows: Audit Committee: David Natan (Chair), Eric Greenberg, Matthew McMurdo, Compensation Committee: Matthew McMurdo (Chair), Peter Chasey, David Natan and Nominating and Governance Committee: Avraham Ben-Tzvi (Chair), Peter Chasey, Eric Greenberg.
New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.1m free cash flow). Negative equity (-US$312k). Revenue is less than US$1m (US$463k revenue). Market cap is less than US$10m (US$9.76m market cap). Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding).
공시 • Jun 07Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)On June 5, 2023, Titan Pharmaceuticals, Inc. received a letter (the “Extension Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it had been granted an additional 180-day period, or until October 2, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1). As previously disclosed on April 11, 2023, the Company received a notice (the “Notice”) on April 5, 2023 from the Staff notifying the Company that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2022 (“2022 10-K”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2,500,000 (the “Stockholders’ Equity Requirement”). In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy the Stockholders’ Equity Requirement. The Company submitted a plan to regain compliance with the Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1) on May 22, 2023. Pursuant to the Extension Notice, the Company must demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) on or before October 2, 2023, by furnishing to the Securities and Exchange Commission (the “SEC”) and Nasdaq certain information and representations on a Current Report on Form 8-K, among other obligations. If, after submitting this information to the SEC and Nasdaq as described in the Extension Notice, the Company fails to evidence compliance with Nasdaq Listing Rule 5550(b)(1) upon filing its Form 10-K for the year ended December 31, 2023, the Company may be subject to delisting from Nasdaq. In the event the Company fails to regain compliance, Nasdaq will issue the Company a delisting notice, at which time the Company would have the right to a hearing before an independent panel. The hearing request would halt any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.
Reported Earnings • May 18First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022)First quarter 2023 results: US$0.11 loss per share (improved from US$0.24 loss in 1Q 2022). Revenue: US$98.0k (down 49% from 1Q 2022). Net loss: US$1.68m (loss narrowed 34% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Jan 28Principal Executive Officer recently bought US$56k worth of stockOn the 25th of January, David Lazar bought around 58k shares on-market at roughly US$0.98 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. David has been a buyer over the last 12 months, purchasing a net total of US$3.9m worth in shares.
Board Change • Nov 17Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Jim McNab was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Aug 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Jim McNab was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Aug 12Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021)Second quarter 2022 results: US$0.18 loss per share (down from US$0.17 loss in 2Q 2021). Revenue: US$150.0k (down 66% from 2Q 2021). Net loss: US$2.46m (loss widened 47% from 2Q 2021). Over the next year, revenue is expected to shrink by 87% compared to a 16% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
분석 기사 • Jul 10Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Recent Insider Transactions • Jul 09Insider recently bought US$1.7m worth of stockOn the 7th of July, David Lazar bought around 2m shares on-market at roughly US$0.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$3.8m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jun 10Insider recently bought US$348k worth of stockOn the 8th of June, David Lazar bought around 752k shares on-market at roughly US$0.46 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$506k more in shares than they have sold in the last 12 months.
Reported Earnings • May 18First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021)First quarter 2022 results: US$0.24 loss per share (up from US$0.28 loss in 1Q 2021). Revenue: US$192.0k (down 72% from 1Q 2021). Net loss: US$2.54m (loss narrowed 3.8% from 1Q 2021).
Recent Insider Transactions • Apr 27Insider recently bought US$157k worth of stockOn the 18th of April, David Lazar bought around 171k shares on-market at roughly US$0.92 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Mar 28Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020)Full year 2021 results: US$0.90 loss per share. Revenue: US$1.53m (down 69% from FY 2020). Net loss: US$8.78m (loss widened 19% from FY 2020).
Reported Earnings • Nov 21Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: US$264.0k (down 74% from 3Q 2020). Net loss: US$1.92m (loss widened 32% from 3Q 2020).
Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: US$445.0k (down 66% from 2Q 2020). Net loss: US$1.68m (loss narrowed 64% from 2Q 2020).
Reported Earnings • May 19First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: US$682.0k (down 49% from 1Q 2020). Net loss: US$2.64m (loss narrowed 53% from 1Q 2020).
Is New 90 Day High Low • Mar 05New 90-day low: US$2.88The company is down 18% from its price of US$3.50 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.
